Qingbei Zeng

USPTO Granted Patents = 17 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 11 (Patent Applications = 9)

Average Co-Inventor Count = 9.8

ph-index = 7

Forward Citations = 139(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

5 out of 52

Pharmacopeia Drug Discovery, Inc.

where one patent can have more than one assignee

Years Active: 2005-2015

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8980920 - Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C (2015-03-17),

2. 8901139 - Tricyclic indole derivatives and methods of use thereof (2014-12-02),

3. 8772505 - Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C (2014-07-08),

4. 8614229 - Substituted indole derivatives and methods of use thereof (2013-12-24),

5. 8609635 - Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases (2013-12-17),

6. 8557848 - 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections (2013-10-15),

7. 8207170 - Heterocyclic substituted piperazines with CXCR3 antagonist activity (2012-06-26),

8. 8143305 - 2,3-substituted indole derivatives for treating viral infections (2012-03-27),

9. 7879838 - Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity (2011-02-01),

10. 7868006 - Heterocyclic substituted piperazines with CXCR3 antagonist activity (2011-01-11),

11. 7868005 - Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity (2011-01-11),

12. 7799789 - Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity (2010-09-21),

13. 7417045 - Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity (2008-08-26),

14. 7238688 - Piperidine compounds (2007-07-03),

15. 7220735 - [object Object] (2007-05-22),

Title: Unveiling the Inventive Mind of Qingbei Zeng

Introduction: Qingbei Zeng, a prolific inventor hailing from Edison, NJ, is making waves in the field of pharmaceutical innovation with a remarkable portfolio of 17 patents to his name.

Latest Patents: Among his latest groundbreaking patents is the development of antiviral compounds with three linked aryl moieties, targeting diseases such as hepatitis C. These novel Linked Tricyclic Aryl Compounds have shown promise in treating and preventing HCV infection, with compounds like compound 56 leading the way. Additionally, Zeng has delved into the realm of Tricyclic Indole Derivatives, offering innovative methods for combating viral infections and virus-related disorders.

Career Highlights: Zeng has left an indelible mark on renowned companies such as Schering Corporation and Merck Sharp & Dohme Corporation, where his innovative spirit and dedication have shone through in his pioneering work.

Collaborations: Throughout his illustrious career, Zeng has collaborated with esteemed professionals in the field, including the likes of Stuart B. Rosenblum and Joseph A. Kozlowski. These partnerships have facilitated the exchange of ideas and expertise, leading to the development of cutting-edge solutions in the pharmaceutical landscape.

Conclusion: Qingbei Zeng stands as a beacon of ingenuity in the realm of pharmaceutical innovation, with his trailblazing patents and collaborations underscoring his unwavering commitment to advancing the field. His contributions continue to inspire and pave the way for transformative breakthroughs in healthcare and beyond.

This text is generated by artificial intelligence and may not be accurate.